Eva Akurut

Ms. Eva Akurut

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Eva AkurutEva Akurut
Eva Akurut
YGYahaya Gavamukulya
Yahaya Gavamukulya
JMJulius Mulindwa
Julius Mulindwa
MIMoses Isiagi
Moses Isiagi
RGRonald Galiwango
Ronald Galiwango
Gerald MboowaGerald Mboowa
Gerald Mboowa
The global burden of Mycobacterium tuberculosis (M. tuberculosis) and Mycobacterium bovis (M. bovis), the rise of drug-resistant strains, necessitates an urgent need for developing more effective vaccines. This study employed an in-silico approach to design a multi-epitope vaccine targeting the PE_PGRS16 protein, a conserved virulence factor found across both species, including drug-resistant strains. PE_PGRS16 was chosen due to its extracellular localization, adhesion properties, and virulence characteristics, making it a promising vaccine target. Epitopes for B-cells, Cytotoxic T Lymphocytes, and Helper T Lymphocytes were selected based on antigenicity, non-toxicity, and immune response potential. The vaccine construct demonstrated favorable properties, including high antigenicity, solubility, and stability, with a low instability index (-31.31) and binding energy (-44.566) when docked to TLR4, suggesting its potential for immune activation. Griselimycin was incorporated as an adjuvant to enhance immunogenicity, as predicted by C-ImmSim simulations. Population coverage analysis for East Africa revealed high applicability, with 98.35% coverage for Class I epitopes, 100% coverage for Class II epitopes, and 100% combined coverage, with average hit values of 8.4, 12.26, and 20.66, respectively. These results suggest broad potential for global vaccine deployment. This study presents a novel multi-epitope vaccine targeting PE_PGRS16, with the potential to combat Mycobacterium tuberculosis and Mycobacterium bovis infections, including drug-resistant forms. Further experimental validation is necessary to confirm its efficacy and safety.

8 July 2025 in Scientific Reports
Verified
Journal Article
Open access
KCKimberly C. Coetzer
Kimberly C. Coetzer
FZFiras Zemzem
Firas Zemzem
Eva AkurutEva Akurut
Eva Akurut
GWGideon Akuamoah Wiafe
Gideon Akuamoah Wiafe
OAOlaitan I. Awe
Olaitan I. Awe
Following a confirmed genetic diagnosis, rare disease patients and their families encounter significant challenges in accessing diagnostic information and support. Patients and non-specialists are increasingly expected to interpret and share test results; however, existing standards are primarily designed for specialists. These standards fail to address the needs of resource-limited populations where low genomic literacy hampers accurate dissemination of genetic results. This research introduces RareInsight, an open-source, interactive dashboard designed to enhance the accessibility, comprehension, and collaboration of genetic data among patients, caregivers, clinicians, and researchers. Developed using shinydashboard, RareInsight was evaluated using whole exome sequencing data from skeletal dysplasia patients. It allows users to input and view Variant Call Format files and includes a searchable ClinVar variant table with filtering options, providing access to multiple resources based on search terms. RareInsight aims to simplify the dissemination of complex genetic information beyond the clinical setting. This dashboard serves as a pilot study demonstrating the potential of patient-centered interactive dashboards for the rare disease community.

25 February 2026 in Communications Biology
Verified
Journal Article
Open access
PDF file
JAJustice O. Amofa
Justice O. Amofa
JGJuergen George
Juergen George
NONoella A. Okumu
Noella A. Okumu
MOMoses Ohene
Moses Ohene
Ermias Mergia TerefeErmias Mergia Terefe
Ermias Mergia Terefe
ENEmmanuel Nji
Emmanuel Nji
Artificial intelligence is rapidly transforming structural biology and accelerating access to protein structures, yet many Africa-based scientists still lack infrastructure, training opportunities, and sustained mentorship to fully benefit. Here, we describe BioStruct-Africa’s community-driven framework integrating AlphaFold, experimental structural biology, and computational drug design to train 1000 scientists over the next decade.

4 September 2025 in African Journal of Thoracic and Critical Care Medicine
Verified
Journal Article
Open access
PDF file
Moses IsiagiMoses Isiagi
Moses Isiagi
KOKufre Okop
Kufre Okop
KDK Dikgomo
K Dikgomo
FBF M Bickton
F M Bickton
JRJamie Rylance
Jamie Rylance
RZR Van Zyl-Smit
R Van Zyl-Smit
Background. In Africa, with a high burden of chronic obstructive pulmonary disease (COPD), access to medication and availability and use of pulmonary rehabilitation (PR) intervention, including awareness of its effectiveness, remain limited.Objectives. To evaluate the extent of clinical awareness and knowledge of and support for PR among healthcare providers, and to identify barriers to PR in Africa. Methods. A comprehensive electronic survey was conducted to assess healthcare providers (HCPs)’ beliefs about, knowledge, awareness and utilisation of, and access to PR in Africa, to inform strategies and policies for improved COPD prevention. The survey was adapted and validated for the African context through expert review and pilot testing with regional practitioners. It was then distributed to HCPs in clinical practice through the networks of the South African Thoracic Society and the Pan African Thoracic Society across Africa. Results. Data were received from 108 HCPs representing diverse disciplines across rural and urban locations in 23 African countries (response rate 56%). The median (interquartile range) age was 41.0 (37.0 - 48.5) years, with no significant differences between the locations. Almost all the HCPs (98%) acknowledged the necessity of PR for severe pulmonary disease, and 58% expressed the need to improve their knowledge and skills in this area. Significant barriers such as under-reporting of symptoms by patients (74%) and a lack of easy access to spirometry (53%) were reported, hindering access to and diagnosis and rehabilitation of patients with COPD. Conclusion. The substantial awareness and recognition of PR as an effective intervention for COPD and other chronic lung diseases across Africa is remarkable. It could indicate the feasible benefits that HCPs attach to implementing comprehensive PR in African settings. Equipping all HCPs with the requisite skills to implement an effective, locally acceptable PR programme will mitigate the burden of COPD in Africa.

14 January 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
PNPatricia Nabisubi
Patricia Nabisubi
SKStephen Kanyerezi
Stephen Kanyerezi
HAHerbert Agasi
Herbert Agasi
SKShahiid Kiyaga
Shahiid Kiyaga
Eva AkurutEva Akurut
Eva Akurut
RGRonald Galiwango
Ronald Galiwango
COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus, which put the entire world on hold for two years from 2020 to March 2022 before the rapid roll-out of vaccines. This virus claimed many lives, 6,331,727 deaths globally, and 172,390 people in Africa died from the disease, while Uganda lost 3,620 people in the same period. The study aimed to analyse the spread patterns of SARS-CoV-2 in Uganda and neighbouring countries and understand the community transmission within Uganda. The study utilised genomic sequences from the Global Initiative on Sharing Avian Influenza Data (GISAID) repository. Bayesian Phylogeography methods were used via the BEAST software. The first case of COVID-19 in Uganda likely originated from Kenya. The virus spread from Kenya to other East African countries. Cross-border movements, especially by truck drivers and refugees, played a significant role in the spread. The study highlights the importance of cross-border collaborations to control infectious disease spread. The spread pattern was influenced by trade routes and the movement of people, emphasising the need for robust border control measures during pandemics. Understanding the origin and spread of SARS-CoV-2 can inform better public health strategies and preparedness for future pandemics.

14 October 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
FAFolagbade Abitogun
Folagbade Abitogun
RSR. Srivastava
R. Srivastava
SSS. Sharma
S. Sharma
VKV. Komarysta
V. Komarysta
Eva AkurutEva Akurut
Eva Akurut
SDS. Debnath
S. Debnath
The COVID19 pandemic has resulted in 1,092,342 deaths as of 14 th October 2020, indicating the urgent need for a vaccine. This study highlights novel protein sequences generated by shot gun sequencing protocols that could serve as potential antigens in the development of novel subunit vaccines and through a stringent inclusion criterion, we characterized these protein sequences and predicted their 3D structures. We found distinctly antigenic sequences from the SARS-CoV-2 that have led to identification of 4 proteins that demonstrate an advantageous binding with Human leukocyte antigen-1 molecules. Results show how previously unexplored proteins may serve as better candidates for subunit vaccine development due to their high stability and immunogenicity, reinforce by their HLA-1 binding propensities and low global binding energies. This study thus takes a unique approach towards furthering the development of vaccines by employing multiple consensus strategies involved in immuno-informatics technique.